NATIONAL: Cough Syrup Deaths: Centre Warns Pharma Firms of Shutdown
A heartbreaking wave of child deaths from tainted cough syrup has gripped India, spotlighting deep flaws in drug production.
Over 20 young lives lost in Madhya Pradesh have ignited national outrage and global scrutiny.
This tragedy underscores the urgent need for stricter safeguards in the pharmaceutical sector.
The Heartbreaking Toll in Madhya Pradesh
In Chhindwara district, at least 23 children succumbed after taking Coldrif cough syrup, contaminated with toxic diethylene glycol.
Families report symptoms like vomiting and organ failure striking swiftly after use.
Health officials link the outbreak directly to this syrup, distributed widely in local clinics.
The contamination level stunned investigators: tests revealed 48.6 percent diethylene glycol in samples, far exceeding safe limits.
This industrial solvent, cheap but deadly, has poisoned products before, yet oversight failed here. Parents now demand justice amid grief.
Scrutiny on Sresan Pharma’s Operations
The syrup came from Sresan Pharmaceutical Manufacturer in Kanchipuram, Tamil Nadu, a unit under heavy fire.
Inspections uncovered over 300 regulatory breaches, including poor supervision and outdated methods. No quality checks allowed the poison to slip into batches.
Tamil Nadu authorities swiftly revoked the company’s licenses, halting all production.
Police arrested the owner, who is facing charges of negligence leading to deaths.
This action signals zero tolerance, but questions linger on how such lapses evaded earlier audits.
Echoes from Past Global Incidents
India’s exports have drawn fire before, with child deaths in Gambia, Uzbekistan, and Cameroon tied to similar syrups.
Those cases exposed reliance on old manufacturing practices, ignoring World Health Organization guidelines. International bodies now press for accountability.
The pattern repeats: cutting corners with toxic substitutes like diethylene glycol.
WHO recently flagged regulatory gaps, urging faster reforms. This domestic crisis amplifies calls for India to lead in safe drug standards worldwide.
Central Government’s Decisive Response
Responding to mounting pressure, the Central Drugs Standard Control Organization issued a stark directive on November 7.
All drug makers must adopt global Good Manufacturing Practices by January 1, 2026, or face shutdowns. No further delays will be granted.
This builds on revised Schedule M rules, aligning with WHO norms for hygiene, validation, and traceability.
Larger firms met earlier targets, but smaller ones get this final push. State controllers must inspect facilities nationwide to enforce compliance.
Implications for Public Health and Industry
These steps aim to restore trust in India’s vast pharma industry, a global supplier of affordable medicines.
Yet challenges remain: upgrading small units costs millions, straining resources. Success hinges on rigorous enforcement and tech adoption.
For families scarred by loss, this feels like too little, too late. Broader reforms could prevent future horrors, saving lives through proactive vigilance.
As the deadline nears, the sector watches closely, knowing failure invites more tragedy.